CLINICAL_TRIALS
trial_result
· 2022-09-21
Clinical Trial Update: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) [Phase 3]
Summary
Phase 3 trial results for topical ruxolitinib (Opzelura) in non-segmental vitiligo have been posted following completion of TRuE-V1.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Incyte Corporation | Conditions: Non-segmental Vitiligo | Phase 3 | Status: COMPLETED | Results posted: 2022-09-21